Cargando…

Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study

OBJECTIVE: To evaluate the association between metformin use and anemia risk in type 2 diabetes, and the time-course for this, in a randomized controlled trial (RCT) and real-world population data. RESEARCH DESIGN AND METHODS: Anemia was defined as a hemoglobin measure of <11 g/dL. In the RCTs A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Donnelly, Louise A., Dennis, John M., Coleman, Ruth L., Sattar, Naveed, Hattersley, Andrew T., Holman, Rury R., Pearson, Ewan R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2020
Materias:	Epidemiology/Health Services Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510037/ https://www.ncbi.nlm.nih.gov/pubmed/32801130 http://dx.doi.org/10.2337/dc20-1104

Ejemplares similares

TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol
por: Angwin, Catherine, et al.
Publicado: (2020)

Costs and Treatment Pathways for Type 2 Diabetes in the UK: A Mastermind Cohort Study
por: Eibich, Peter, et al.
Publicado: (2017)

What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study
por: McGovern, Andrew P., et al.
Publicado: (2019)

Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data
por: Leal, Jose, et al.
Publicado: (2020)

Patient preference for second and third line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study
por: Shields, Beverley M, et al.
Publicado: (2023)

Metformin and breast and gynecological cancer risk among women with diabetes
por: Soffer, Diana, et al.
Publicado: (2015)

Association of vitamin B(12) deficiency in people with type 2 diabetes on metformin and without metformin: a multicenter study, Karachi, Pakistan
por: Miyan, Zahid, et al.
Publicado: (2020)

Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010–2017
por: Dennis, John M., et al.
Publicado: (2019)

Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas
por: Mamtani, Ronac, et al.
Publicado: (2014)

Patient stratification for determining optimal second and third line therapy for type 2 diabetes: the TriMaster study
por: Shields, Beverley M, et al.
Publicado: (2023)

The impact of birthweight on subsequent phenotype of type 2 diabetes in later life
por: Paulina, Christian, et al.
Publicado: (2022)

Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
por: McGovern, Andrew P, et al.
Publicado: (2020)

Type 2 Diabetes and COVID-19–Related Mortality in the Critical Care Setting: A National Cohort Study in England, March–July 2020
por: Dennis, John M., et al.
Publicado: (2021)

Use of metformin following a population-level intervention to encourage people with pre-diabetes to enroll in the National Diabetes Prevention Program
por: Hurst, Thomas E, et al.
Publicado: (2021)

Trajectories in HbA1c and other risk factors among adults with type 1 diabetes by age at onset
por: Edqvist, Jon, et al.
Publicado: (2021)

The Impact of Carbamylation and Anemia on HbA(1c)’s Association With Renal Outcomes in Patients With Diabetes and Chronic Kidney Disease
por: Tang, Mengyao, et al.
Publicado: (2023)

Comparative effect of metformin versus sulfonylureas with dementia and Parkinson’s disease risk in US patients over 50 with type 2 diabetes mellitus
por: Newby, Danielle, et al.
Publicado: (2022)

Lifestyle and Metformin Interventions Have a Durable Effect to Lower CRP and tPA Levels in the Diabetes Prevention Program Except in Those Who Develop Diabetes
por: Goldberg, Ronald B., et al.
Publicado: (2014)

Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study
por: Au Yeung, Shiu Lun, et al.
Publicado: (2019)

Associations between grip strength and incident type 2 diabetes: findings from the UK Biobank prospective cohort study
por: Boonpor, Jirapitcha, et al.
Publicado: (2021)

Anemia and incidence of dementia in patients with new-onset type 2 diabetes: a nationwide population-based cohort study
por: Choi, Jae Woo, et al.
Publicado: (2020)

Metformin Use in Prediabetes Among U.S. Adults, 2005–2012
por: Tseng, Eva, et al.
Publicado: (2017)

Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas
por: Chu, Patricia Y., et al.
Publicado: (2020)

Potential Impact of Prescribing Metformin According to eGFR Rather Than Serum Creatinine
por: Tuot, Delphine S., et al.
Publicado: (2015)

Leptin Predicts Diabetes but Not Cardiovascular Disease: Results from a large prospective study in an elderly population
por: Welsh, Paul, et al.
Publicado: (2009)

Health Beliefs Associated With Metformin Use Among Insured Adults With Prediabetes
por: McEwen, Laura N., et al.
Publicado: (2022)

Novel subgroups of type 2 diabetes and their association with microvascular outcomes in an Asian Indian population: a data-driven cluster analysis: the INSPIRED study
por: Anjana, Ranjit Mohan, et al.
Publicado: (2020)

Can peer support be cost saving? An economic evaluation of RAPSID: a randomized controlled trial of peer support in diabetes compared to usual care alone in East of England communities
por: Wingate, La’Marcus, et al.
Publicado: (2017)

Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2020)

Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK
por: Gonzalez Perez, Antonio, et al.
Publicado: (2023)

Assessment of diabetes and prediabetes prevalence and predictors by HbA1c in a population from sub-Saharan Africa with a high proportion of anemia: a prospective cross-sectional study
por: Hodel, Nikolai Carl, et al.
Publicado: (2020)

Association between metformin and neurodegenerative diseases of observational studies: systematic review and meta-analysis
por: Ping, Fan, et al.
Publicado: (2020)

Contribution of type 2 diabetes to all-cause mortality, cardiovascular disease incidence and cancer incidence in white Europeans and South Asians: findings from the UK Biobank population-based cohort study
por: Muilwijk, Mirthe, et al.
Publicado: (2019)

Major malformations risk following early pregnancy exposure to metformin: a systematic review and meta-analysis
por: Abolhassani, Nazanin, et al.
Publicado: (2023)

Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study
por: Gordon, Jason, et al.
Publicado: (2018)

Prevalence, control, and treatment of diabetes, hypertension, and high cholesterol in the Amish
por: He, Shisi, et al.
Publicado: (2020)

Cohort profile for the MASTERMIND study: using the Clinical Practice Research Datalink (CPRD) to investigate stratification of response to treatment in patients with type 2 diabetes
por: Rodgers, Lauren R, et al.
Publicado: (2017)

Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA
por: Singhal, Mukul, et al.
Publicado: (2019)

Racial/Ethnic Differences in Dementia Risk Among Older Type 2 Diabetic Patients: The Diabetes and Aging Study
por: Mayeda, Elizabeth R., et al.
Publicado: (2014)

Midsummer mysteries: Criminal masterminds? Not really…
por: Antonella Del Rosso
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2e5cpd5bnra0sfeo2ks682g3dh